Suven Life Sciences Ltd

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 March 2026, providing investors with the latest insights into its performance and outlook.

Suven Life Sciences Ltd, a key player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, with multiple indicators signalling a bearish trend. The company’s MarketsMOJO grade has been downgraded from Sell to Strong Sell as of 6 August 2025, reflecting growing concerns over its near-term price trajectory despite its strong long-term returns relative to the Sensex.

Suven Life Sciences Ltd has exhibited a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a modest day gain of 0.97%, the stock’s broader trend signals and momentum oscillators suggest cautious investor sentiment amid mixed signals from key technical parameters.

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Suven Life Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a strong long-term return profile, recent technical parameters suggest caution for investors as the stock navigates a challenging phase in the Healthcare Services sector.

Suven Life Sciences Ltd, a key player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across multiple timeframes. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s long-term returns continue to outperform the Sensex, underscoring the nuanced nature of its current market positioning.

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 August 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Suven Life Sciences Ltd has experienced a notable shift in price momentum, reflected in a complex mix of technical indicators that suggest a transition from bearish to mildly bearish trends. Despite a strong day change of 15.27%, the stock’s technical parameters reveal a nuanced outlook, with some indicators signalling caution while others hint at potential recovery.

Suven Life Sciences Ltd demonstrated robust intraday performance on 4 Feb 2026, surging to an intraday high of Rs 163.05, marking a significant 10.45% increase from the previous close. The stock outperformed its sector and broader market indices amid heightened volatility and positive trading momentum.

Suven Life Sciences Ltd has experienced a notable shift in price momentum, with technical indicators signalling a predominantly bearish outlook despite a recent sharp price rise. The stock’s technical trend has deteriorated from mildly bearish to bearish, reflecting growing caution among investors amid mixed signals from key momentum and volume indicators.

Suven Life Sciences Ltd recorded a robust intraday rally on 3 Feb 2026, surging to an intraday high of Rs 149.2, marking an 8.39% increase from its previous close. The stock outperformed its sector and the broader market, reflecting strong trading momentum throughout the session.

Suven Life Sciences Ltd witnessed a robust start to the trading session on 3 Feb 2026, opening with a notable gap up of 5.34%, reflecting positive market sentiment within the Healthcare Services sector. The stock’s intraday performance demonstrated sustained momentum, outperforming both its sector peers and the broader Sensex index.

Suven Life Sciences Ltd (NSE: 588414) is currently navigating a complex technical landscape as recent momentum indicators reveal a shift from bearish to mildly bearish trends. Despite a strong long-term return profile, the stock’s near-term technical parameters suggest caution for investors amid mixed signals from MACD, RSI, and moving averages.

Suven Life Sciences Ltd demonstrated robust intraday performance on 1 Feb 2026, surging 7.3% to touch a day’s high of Rs 141.9, significantly outperforming the broader Sensex which gained a modest 0.08% during the session.

Suven Life Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 August 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 February 2026, providing investors with the latest insights into its performance and prospects.

Suven Life Sciences Ltd., a Hyderabad-based healthcare services company, reported catastrophic losses in Q3 FY26, with net profit plunging to a staggering ₹101.92 crores loss—its worst quarterly performance on record. The devastating results, marking a 50.06% sequential deterioration from Q2 FY26's ₹77.31 crores loss, have sent the stock into a prolonged bearish spiral, with shares trading at ₹130.80 as of January 29, 2026, down 56.83% from their 52-week high of ₹303.00.